首页> 外文OA文献 >Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin
【2h】

Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin

机译:基于多孔渗透泵的奥昔布宁控释系统的研制与优化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the current study was to design a porous osmotic pump-based drug delivery system for controlled release of oxybutynin. The porous osmotic pump contains pore-forming water-soluble additives in the coating membrane, which after coming in contact with water, dissolve, resulting in an in situ formation of a microporous structure. The dosage regimen of oxybutynin is one 5-mg tablet 2 to 3 times a day. The plasma half-life ranges from ∼2 to 3 hours. Hence, oxybutynin was chosen as a model drug with an aim to develop a controlled release system for a period of 24 hours. Linear and reproducible release similar to that of Ditropan XL was achieved for optimized formulation (f2>50) independent of hydrodynamic conditions. The effect of different formulation variables, namely, ratio of drug to osmogent, membrane weight gain, and level of pore former on the in vitro release was studied. Cellulose acetate (CA) was used as the semipermeable membrane. It was found that drug release rate increased with the amount of osmogent because of the increased water uptake, and hence increased driving force for drug release. Oxybutynin release was inversely proportional to the membrane weight gain; however, directly related to the level of pore former, sorbitol, in the membrane. This system was found to deliver oxybutynin at a zero-order rate for 20 hours. The effect of pH on drug release was also studied. The optimized formulations were subjected to stability studies as per International Conference on Harmonisation (ICH) guidelines and formulations were stable after a 3 month study.
机译:当前研究的目的是设计一种基于多孔渗透泵的药物递送系统,用于奥昔布宁的控制释放。多孔渗透泵在涂膜中包含成孔的水溶性添加剂,该添加剂与水接触后溶解,从而形成微孔结构的原位形成。奥昔布宁的剂量方案是每天5片,每次2至3次。血浆半衰期约为2至3小时。因此,选择奥昔布宁作为模型药物,目的是开发24小时控释系统。对于独立于流体动力学条件的优化配方(f2> 50),可实现类似于Ditropan XL的线性释放和可再现释放。研究了不同制剂变量(即药物与渗透剂的比率,膜重量增加和成孔剂水平)对体外释放的影响。乙酸纤维素(CA)用作半透膜。已经发现,由于吸水量的增加,药物的释放速率随渗透剂量的增加而增加,因此药物释放的驱动力也增加。奥昔布宁的释放与膜的重量增加成反比。但是,它与膜中造孔剂山梨醇的含量直接相关。发现该系统以零级速率递送奥昔布宁20小时。还研究了pH对药物释放的影响。根据国际协调会议(ICH)的指导原则,对优化的制剂进行稳定性研究,并且在进行3个月的研究后,制剂保持稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号